演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

Analysis of efficacy of autologous peripheral blood stem cell transplantation in malignant lymphoma

演題番号 : PS-1-240

高橋 渉 (Wataru Takahashi):1、仲村 祐子 (Yuko Nakamura):1、杉田 英子 (Fusako Sugita):1、鴇田 勝哉 (Katsuya Tokita):1、礒 桐子 (Hisako Iso):1、新井 ほのか (Honoka Arai):1、鶴見 茂治 (Shigeharu Tsurumi):1、田所 治朗 (Jirou Tadokoro):2、半田 智幸 (Tomoyuki Handa):1、中村 由香 (Yuka Nakamura):1、中村 幸嗣 (Yukitsugu Nakamura):1、佐々木 光 (Ko Sasaki):1、三谷 絹子 (Kinuko Mitani):1

1:Department of Haematology and Oncology, Dokkyo Medical University, Mibu, Japan、2:Shinmatsudo Central General Hospital, Matsudo, Japan

 

Autologous peripheral blood stem cell transplantation (aPBSCT) is regarded as the standard therapy only in a restricted type of malignant lymphoma (ML). In many types and disease status of ML, the efficacy of aPBSCT has not been established. Thus, we retrospectively analyzed the efficacy of aPBSCT in various types and stages of ML in our institute.A total of 34 ML patients (Hodgkin lymphoma (HD): 5 (15%), non-Hodgkin lymphoma (NHL): follicular lymphoma (FL); 3 (9%), diffuse large B-cell lymphoma (DLBCL); 21 (62%), mantle cell lymphoma; 2 (6%), other types; 3 (15%)) were retrospectively analyzed. All these ML patients were diagnosed and treated in our institute from April 2000 to December 2012. Among them, 21 (62%) and 10 (29%) patients received aPBSCT during the period of the first and second complete remission (CR), respectively, and the other 3 (9%) patients without achievement of CR. All HD patients received M-BEAM therapy as conditioning protocol, while 28 of NHL patients MCVC therapy. With a median follow-up duration of 1004 days (range: 77-4425 days), proportion of patients who maintained CR, relapsed and progressed were 26 (76%), 6 (18%) and 2 (6%), respectively. The average survival duration was 3.8 year (FL: 1.7 year, DLBCL: 4.4 year). Only 4 patients died of disease progression (3 patients) or pneumonia (1 patient). In this retrospective analysis, acceptable efficacy of aPBSCT was obtained in ML patients of various disease types and status. This result may indicate the possibility that aPBSCT might be more available in the treatment of ML.

前へ戻る